Trials / Completed
CompletedNCT02491398
Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia
Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 494 (actual)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is intended for Chronic Lymphocytic Leukemia patients who have already undergone a first or second treatment with drugs named bendamustine and rituximab. It will observe the results of this treatment and evaluate its efficacy and side effects.
Detailed description
This cohort study will recruit chronic lymphocytic leukemia (CLL) patients who were treated with first and second-line Bendamustine plus Rituximab (BR) from January 2008 to December 2014 from European centres adhering to the GIMEMA group and the ERIC group, and aims at observing the progression-free survival in CLL patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bendamustine + Rituximab |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2015-07-08
- Last updated
- 2020-10-06
Locations
41 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02491398. Inclusion in this directory is not an endorsement.